NasdaqGS:KNSABiotechs
Kiniksa Pharmaceuticals International (KNSA) After Raised 2026 Guidance And Strong Q2 Results Looks Fully Valued
Kiniksa Pharmaceuticals International (KNSA) drew fresh attention after it raised its 2026 net product revenue guidance to US$980 million to US$995 million, following second quarter results and a company pipeline update.
See our latest analysis for Kiniksa Pharmaceuticals International.
Kiniksa Pharmaceuticals International’s recent guidance hike and strong second quarter results have come after a powerful run, with a year to date share price return of 76.98% and a 1 year total shareholder...